Esteemed epidemiologist: ‘We must start treating immediately’ with hydroxychloroquine

Contrary to popular politicized opinion, hydroxychloroquine can be highly effective against COVID-19, according to a seasoned epidemiology professor at the Yale School of Public Health.

The only caveats are that the much-debated drug must be administered early in the virus’s attack and, when doable, combined with the antibiotics azithromycin or doxycycline and the nutritional supplement zinc.

So maintains Harvey A. Risch, MD, PhD, whose credentials include authoring more than 300 peer-reviewed studies and holding senior positions on editorial boards at several leading scientific journals.

Risch’s opinion piece is running in Newsweek.

After summarizing evidence of hydroxychloroquine’s efficacy against COVID and contextualizing widely disseminated warnings about its potential for causing cardiac arrhythmia, Risch pleads with the public to place hard science over hot passion.

“In the future, I believe this misbegotten episode regarding hydroxychloroquine will be studied by sociologists of medicine as a classic example of how extra-scientific factors overrode clear-cut medical evidence. But for now, reality demands a clear, scientific eye on the evidence and where it points,” he writes.

“For the sake of high-risk patients, for the sake of our parents and grandparents, for the sake of the unemployed, for our economy and for our polity, especially those disproportionally affected, we must start treating immediately.”

Click here to read the whole thing.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”